Diabetic retinopathy: current understanding, mechanisms, and treatment strategies.
By E. Duh, Jennifer K. Sun, Alan W. Stitt. JCI Insight, 2017
960 citations recorded by the source corpus.
Diabetic retinopathy (DR) causes significant visual loss on a global scale. Treatments for the vision-threatening complications of diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) have greatly improved over the past decade. However, additional therapeutic options are needed that take into account pathology associated with vascular, glial, and neuronal components of the diabetic retina. Recent work indicates that diabetes markedly impacts the retinal neurovascular unit and its interdependent vascular, neuronal, glial, and immune cells. This knowledge is leading to identification of new targets and therapeutic strategies for preventing or reversing retinal neuronal dysfunction, vascular leakage, ischemia, and pathologic angiogenesis. These advances, together with approaches embracing the potential of preventative or regenerative medicine, could provide the means to better manage DR, including treatment at earlier stages and more precise tailoring of treatments based on individual patient variations.
Subfields: Molecular Biology, Ophthalmology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/bba96db3afadf44f0df404adc2876aa0f5c5b52b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Ophthalmology
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- VEGF in Signaling and Disease: Beyond Discovery and Development (2019, background): “The neurovascular complex is best understood in the context of DR, a systemic disease that manifests as end-organ damage in the eye with cell death in both neuronal and vascular elements of the retina (Duh et al., 2017).”